Accumulating active p53 in the nucleus by inhibition of nuclear export: A novel strategy to promote the p53 tumor suppressor function

Experimental Cell Research

Volumn 253, Issue 2, 1999, Pages 315-324

  Laín, Sonia ^a   Xirodimas, Dimitris ^a   Lane, David P ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PROTEIN; PROTEIN P53;

APOPTOSIS; CELL CYCLE; CELL PROLIFERATION; CELL TRANSFORMATION; DNA DAMAGE; DNA REPAIR; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW; SIGNAL TRANSDUCTION;

EID: 0343938848     PISSN: 00144827     EISSN: None     Source Type: Journal    
DOI: 10.1006/excr.1999.4672     Document Type: Review

References (104)

1. Barak Y., Gottlieb E., Juven-Gershon T., Oren M. Regulation of mdm2 expression by p53: Alternative promoters produce transcripts with nonidentical translation potential. Genes Dev. 8:1994;1739-1749.
2. Bates S., Vousden K. H. Mechanisms of p53-mediated apoptosis. Cell. Mol. Life Sci. 55:1999;28-37.
3. Bottger A., Bottger V., Garcia-Echeverria C., Chene P., Hochkeppel H. K., Sampson W., Ang K., Howard S. F., Picksley S. M., Lane D. P. Molecular characterization of the hdm2-p53 interaction. J. Mol. Biol. 269:1997a;744-756.
4. Bottger A., Bottger V., Sparks A., Liu W-L., Howard S. F., Lane D. Peptide aptamers that disrupt the interaction between mdm2 and p53 in vivo activate p53 dependent transcription and inhibit p53 degradation. Curr. Biol. 7:1997b;860-869.
5. Caelles C., Helmberg A., Karin M. p53-dependent apoptosis in the absence of transcriptional activation of p53-target genes. Nature. 370:1994;220-223.
6. Cohen P. The search for physiological substrates of MAP and SAP kinases in mammalian cells. Trends Cell. Biol. 7:1997;353-361.
7. Chang Y. C., Lee Y. S., Tejima T., Tanaka K., Omura S., Heintz N. H., Mitsui Y., Magae J. Mdm2 and bax, downstream mediators of the p53 response, are degraded by the ubiquitin-proteasome pathway. Cell Growth Differ. 9:1998;79-84.
8. Chen L., Lu W., Agrawal S., Zhou W., Zhang R., Chen J. Ubiquitous induction of p53 in tumour cells by antisense inhibition of MDM2 expression. Mol. Med. 5:1999;21-34.
9. Coux O., Tanaka K., Goldberg A. L. Structure and functions of the 20S and the 26S proteasomes. Annu. Rev. Biochem. 65:1996;801-847.
10. Crook T., Parker G. A., Rozycka M., Crossland S., Allday M. J. A transforming p53 mutant, which binds DNA, transactivates and induces apoptosis reveals a nuclear:cytoplasmic shuttling defect. Oncogene. 16:1998;1429-1441.
11. Dang C. V., Lee W. M. Nuclear and nucleolar sequences of c-erb-A, c-myb, N-myc, p53. HSP70, and HIV tat proteins. J. Biol. Chem. 264:1989;18019-18023.
12. David-Pfeuty T., Chakrani F., Ory K., Nouvian-Dooghe Y. Cell cycle-dependent regulation of nuclear p53 traffic occurs in one subclass of human tumour cells and in untransformed cells. Cell Growth Differ. 7:1996;1211-1225.
13. Dulic V., Kaufmann W. K., Wilson S. J., Tlsty T. D., Lees E., Harper J. W., Elledge S. J., Reed S. I. p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell. 76:1994;1013-1023.
14. el-Deiry W. S., Tokino T., Velculescu V. E., Levy D. B., Parsons R., Trent J. M., Lin D., Mercer W. E., Kinzler K. W., Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell. 75:1993;817-825.
15. Engel K., Kotlyarov A., Gaestel M. Leptomycin B-sensitive nuclear export of MAPKAP kinase 2 is regulated by phosphorylation. EMBO J. 17:1998;3363-3371.
16. Fischer U., Huber J., Boelens W. C., Mattaj I. W., Lührmann R. The HIV-1 Rev activation domain is a nuclear export signal that accesses an export pathway used by specific cellular RNAs. Cell. 82:1995;475-483.
17. Flamini G., Curigliano G., Ratto C., Astone A., Ferretti G., Nucera P., Sofo L., Sgambato A., Boninsegna A., Crucitti F., Cittadini A. Prognostic significance of cytoplasmic p53 overexpression in colorectal cancer. An immunohistochemical analysis. Eur. J. Cancer. 32A:1996;802-806.
18. Fornerod M., Ohno M., Yoshida M., Mattaj I. W. CRM1 is an export receptor for leucine-rich nuclear export signals. Cell. 90:1997;1051-1060.
19. Freedman D. A., Levine A. J. Nuclear export is required for degradation of endogenous p53 by MDM2 and human papillomavirus E6. Mol. Cell. Biol. 18:1998;7288-7293.
20. Freedman D. A., Levine A. J. Functions of the MDM2 oncoprotein. Cell. Mol. Life Sci. 55:1999;96-107.
21. Fukuda M., Asano S., Nakamura T., Adachi M., Yoshida M., Yanagida M., Nishida E. CRM1 is responsible for intracellular transport mediated by the nuclear export signal. Nature. 390:1997;308-311.
22. Fukuda M., Gotoh I., Gotoh Y., Nishida E. Cytoplasmic localisation of mitogen-activated protein kinase directed by its NH2-terminal, leucine-rich short amino acid sequence, which acts as a nuclear export signal. J. Biol. Chem. 271:1996;20024-20028.
23. Gannon J. V., Lane D. P. Protein-synthes is required to anchor a mutant p53 protein which is temperature-sensitive for nuclear transport. Nature. 349:1991;802-806.
24. Grenfell S. J., Trausch-Azar J. S., Handley-Gaerhart P. M., Ciechanover A., Schwartz A. L. Nuclear localization of the ubiquitin-activating enzyme, E1, is cell cycle-dependent. Biochem. J. 300:1994;701-708.
25. Hagting A., Karlsson C., Clute P., Jackman M., Pines J. MPF localisation is controlled by nuclear export. EMBO J. 17:1998;4127-4138.
26. Harper J. W., Adami G. R., Wei N., Keyomarsi K., Elledge S. The p21 cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell. 75:1993;805-816.
27. Haupt Y., Maya R., Kazaz A., Oren M. Mdm2 promotes the rapid degradation of p53. Nature. 387:1997;296-299.
28. Haupt Y., Rowan S., Oren M. p53-mediated apoptosis in HeLa cells can be overcome by excess pRB. Oncogene. 10:1995;1563-1571.
29. Hershko A., Ciechanover A. The ubiquitin system. Annu. Rev. Biochem. 67:1998;425-479.
30. Hollstein M., Sidransky D., Vogelstein B., Harris C. C. p53 mutations in human cancers. Science. 253:1991;49-53.
31. ARF with Mdm2 inhibits ubiquitin ligase activity of Mdm2 tumour suppressor p53. EMBO J. 18:1999;22-27.
32. Horak E., Smith K., Bromley L., Lejeune S., Greenall M., Lane D., Harris A. L. Mutant P53, Egf-receptor and C-Erb-2 expression in human breast-cancer. Oncogene. 6:1991;2277-2284.
33. Ishioka C., Englert C., Winge P., Yan Y. X., Engelstein M., Friend S. H. Mutational analysis of the carboxy-terminal portion of p53 using both yeast and mammalian cell assays in vivo. Oncogene. 10:1995;1485-1492.
34. Juven T., Barak Y., Zauberman A., George D. L., Oren M. Wild type p53 can mediate sequence-specific transactivation of an internal promoter within the mdm2 gene. Oncogene. 8:1993;3411-3416.
35. Kharbanda S., Yuan Z. M., Weichselbaum R., Kufe D. Determination of cell fate by c-Abl activation in response to DNA damage. Oncogene. 17:1998;3309-3318.
36. Ko L. J., Prives C. p53: Puzzle and paradigm. Genes Dev. 10:1996;1054-1072.
37. Komarova E. A., Zelnick C. R., Chin D., Zeremski M., Gleiberman A. S., Bacus S. S., Gudkov A. V. Intracellular localization of p53 tumor suppressor protein in γ-irradiated cells is cell cycle regulated and determined by the nucleus. Cancer Res. 57:1997;5217-5220.
38. Kubbutat M. H., Jones S. N., Vousden K. H. Regulation of p53 stability by Mdm2. Nature. 387:1997;299-303.
39. Kudo N., Taoka H., Toda T., Yoshida M., Horinouchi S. A novel nuclear export signal sensitive to oxidative stress in the fission yeast transcription factor Pap1. J. Biol. Chem. 274:1999;15151-15158.
40. Kudo N., Wolff B., Sekimoto T., Schreiner E. P., Yoneda Y., Yanagida M., Horinouchi S., Yoshida M. Leptomycin B inhibition of signal-mediated nuclear export by direct binding to CRM1. Exp. Cell Res. 242:1998;540-547.
41. Kudo N., Khochbin S., Nishi K., Kitano K., Yanagida M., Horinouchi S. Molecular cloning and cell cycle-dependent expression of mammalian CRM1, a protein involved in nuclear export of proteins. J. Biol. Chem. 272:1997;29742-29751.
42. Kuhnt M., Bitsch F., Ponelle M., Sanglier J.-J., Wang Y., Wolff B. Microbial conversion products of leptomycin B. Appl. Environ. Microbiol. 64:1998;714-720.
43. Kumagai A., Dunphy W. G. Binding of 14-3-3 proteins and nuclear export control the intracellular localisation of the mitotic inducer Cdc25. Genes and Dev. 13:1999;1067-1072.
44. Laín S., Midgley C., Sparks A., Lane B., Lane D. P. An inhibitor of nuclear export activates the p53 response and induces the localisation of HDM2 and p53 to U1A-positive nuclear bodies associated with the PODs. Exp. Cell. Res. 248:1999;457-472.
45. Lane D. P. Awakening angels. Nature. 394:1998;616-617.
46. Leopold W. R., Shillis J. L., Mertus A. E., Nelson J. M., Roberts B. J., Jackson R. C. Anticancer activity of the structurally novel antibiotic Ci-920 and its analogues. Cancer Res. 44:1984;1928-1932.
47. Levine A. The cellular gatekeeper for growth and division. Cell. 88:1997;323-331.
48. Liang S. H., Clarke M. F. The nuclear import of p53 is determined by the presence of a basic domain and its relative position to the nuclear localization signal. Oncogene. 18:1999;2163-2166.
49. Liang S. H., Hong D., Clarke M. F. Cooperation of a single lysine mutation and a C-terminal domain in the cytoplasmic sequestration of the p53 protein. J. Biol. Chem. 273:1998;19817-19821.
50. Lin A. W., Barradas M., Stone J. C., van Aelst L., Serrano M., Lowe S. W. Premature senescence involving p53 and p16 is activated in response to constitutive MEK/MAPK mitogenic signaling. Genes Dev. 12:1998;3008-3019.
51. Maki C. G. Oligomerization is required for p53 to be efficiently ubiquitinated by MDM2. J. Biol. Chem. 274:1999;16531-16535.
52. Mattaj I. W., Englmeier L. Nucleocytoplasmic export: The soluble phase. Annu. Rev. Biochem. 67:1998;265-306.
53. Middeler G., Zerf K., Jenovai S., Thulig A., Tschordrich-Rotter M., Kubitscheck U., Peters R. The tumor suppressor p53 is subject both to nuclear import and export, and both are fast, energy-dependent and lectin-inhibited. Oncogene. 14:1997;1407-1417.
54. Midgley C. A., Lane D. P. p53 protein stability in tumour cells is not determined by mutation but is dependent on Mdm2 binding. Oncogene. 15:1997;1179-1189.
55. Mimnaugh E. G., Chen H. Y., Davie J. R., Celis J. E., Neckers L. Rapid deubiquitination of nucleosomal histones in human tumor cells caused by proteasome inhibitors and stress response inducers: Effects on replication, transcription, translation, and the cellular stress response. Biochemistry. 36:1997;14418-14429.
56. Moll U. M., LaQuaglia M., Benard J., Riou G. Wild-type p53 protein undergoes cytoplasmic sequestration in undifferentiated neuroblastomas but not in differentiated tumors. Proc. Natl. Acad. Sci. USA. 92:1995;4404-4411.
57. Moll U. M., Ostermeyer A. G., Haladay R., Winkfield B., Frazier M., Zambetti G. Cytoplasmic sequestration of wild type p53 protein impairs the G1 checkpoint after DNA damage. Mol. Cell. Biol. 16:1996;1126-1137.
58. Moll U. M., Riou G., Levine A. J. Two distinct mechanisms alter p53 in breast-cancer - Mutation and nuclear exclusion. Proc. Natl. Acad. Sci. USA. 89:1992;7262-7266.
59. Mommand J., Zambetti G. P., Olson D. C., George D., Levine A. J. The mdm2 oncogene product forms a complex with p53 protein and inhibits p53-mediated transactivation. Cell. 69:1992;1237-1245.
60. Morgan D. O. Principles of CDK regulation. Nature. 374:1995;131-134.
61. Neville M., Stutz F., Lee L., Davis L. I., Rosbash M. The importin-beta family member Crm1p bridges the interaction between Rev and the nuclear pore complex during nuclear export. Curr. Biol. 7:1997;767-775.
62. Newlands E. S., Rustin G. J. S., Brampton M. H. Phase I trial of elactocin. Br. J. Cancer. 74:1996;648-649.
63. Nurse P. Checkpoint pathways come of age. Cell. 91:1997;865-867.
64. Oliner J. D., Pietenpol J. A., Thiagalingam S., Gyuris J., Kinzler K. W., Vogelstein B. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature. 362:1993;857-860.
65. Ookata K., Hisanaga S., Okano T., Tachibana K., Kishimoto T. Relocation and distinct subcellular localization of p34cdc2-cyclin B complex at meiosis reinitiation in starfish oocytes. EMBO J. 11:1992;1763-1772.
66. Ossareh-Nazari B., Bachelerie F., Dargemont C. Evidence for a role of CRM1 in signal mediated nuclear protein export. Science. 278:1997;141-144.
67. Pines J. Checkpoint on the nuclear frontier. Nature. 397:1999;104-105.
68. Pines J., Hunter T. Human cyclins A and B1 are differentially located in the cell and undergo cell cycle-dependent nuclear transport. J. Cell Biol. 115:1991;1-17.
69. Pines J., Hunter T. The differential localization of human cyclins A and B is due to a cytoplasmic retention signal in cyclin B. EMBO J. 13:1994;3772-3781.
70. Roberts B. J., Hamelehle K. L., Selbolt J. S., Leopold W. R. In vivo and in vitro anticancer activity of the structurally novel and highly potent antibiotic CI-940 and its hydroxy analog. Cancer Chemother. Pharmacol. 16:1986;95-101.
71. Rodriguez M., Thompson J., Hay R. Nuclear retention of IkappaBalpha protects it from signal-induced degradation and inhibits nuclear factor kappaB transcriptional activation. J. Biol. Chem. 274:1999;9108-9115.
72. Rosorius O., Reichart B., Krätzer F., Hegeer P., Dabauvalle M-C., Hauber J. Nuclear pore localization and nucleocytoplasmic transport of eIF-5A: Evidence for direct interaction with the expor receptor CRM1. J. Cell Sci. 112:1999;2369-2380.
73. Roth J., Dobbelstein M., Freedman D. A., Shenk T., Levine A. J. Nucleo-cytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodefficiency virus rev protein. EMBO J. 17:1998;554-564.
74. Runnebaum I. B., Kieback D. G., Mobus V. J., Tong X. W., Kreienberg R. Subcellular localization of accumulated p53 in ovarian cancer cells. Gyn. Oncol. 61:1996;266-271.
75. Scheffner M. Ubiquitin, E6-AP, and their role in p53 inactivation. Pharmacol. Ther. 78:1998;129-139.
76. Scheffner M. Moving proteins heads for breakdown. Nature. 398:1999;103-104.
77. Serrano M., Lin A. W., McCurrach M. E., Beach D., Lowe S. W. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell. 88:1997;593-602.
78. Shaulsky G., Ben-Ze'ev A., Rotter V. Subcellular distribution of the p53 protein during the cell cycle of Balb/C 3T3 cells. Oncogene. 5:1990a;1707-1711.
79. Shaulsky G., Goldfinger N., Benzeev A., Rotter V. Nuclear accumulation of p53 protein is mediated by several nuclear-localization signals and plays a role in tumorigenesis. Mol. Cell. Biol. 10:1990b;6565-6577.
80. Sharpless N. E., DePinho R. A. The INK4a/ARF locus and its two gene products. Curr. Opinion Gen. Dev. 9:1999;22-30.
81. Shvarts A., Bazuine M., Dekker P., Ramos Y. F., Steegenga W. T., Merckx G., van Ham R. C., van der Houven van Oordt W., van der Eb A. J., Jochemsen A. G. Isolation and identification of the human homolog of a new p53-binding protein, Mdmx. Genomics. 43:1997;34-42.
82. Shvarts A., Steegenga W. T., Riteco N., van Laar T., Dekker P., Bazuine M., van Ham R. C., van der Houven van Oordt W., Hateboer G., van der Eb A. J., Jochemsen A. G. MDMX: A novel p53-binding protein with some functional properties of MDM2. EMBO J. 15:1996;5349-5357.
83. Sionov R. V., Moallem E., Berger M., Kazaz A., Gerlitz O., Ben-Neriah Y., Oren M., Haupt Y. c-Abl neutralizes the inhibitory effect of mdm2 on p53. J. Biol. Chem. 274:1999;8371-8374.
84. Stephen A. G., Trausch-Azar J. S., Ciechanover A., Schwartz A. L. The ubiquitin-activating enzyme E1 is phosphorylated and localized to the nucleus in a cell cycle-dependent manner. J. Biol. Chem. 271:1996;15608-15614.
85. Stommel J. M., Marchenko N. D., Jimenez G. S., Moll U. M., Hope T. J., Wahl G. M. A leucine-rich nuclear export signal in the p53 tetramerization domain: regulation of subcellular localization and p53 activity by NES masking. EMBO J. 18:1999;1660-1672.
86. Taagepera S., McDonald D., Loeb J. E., Whitaker L. L., McElroy A. K., Wang J. Y. J., Hope T. J. Nuclear-cytoplasmic shuttling of C-ABL tyrosine kinase. Proc. Natl. Acad. Sci. USA. 95:1998;7457-7462.
87. Tao W., Levine A. J. Nucleocytoplasmic shuttling of oncoprotein Hdm2 is required for Hdm2-mediated degradation of p53. Proc. Natl. Acad. Sci. USA. 96:1999a;3077-3080.
88. ARF stabilizes p53 by blocking nucleocytoplasmic shuttling of Mdm2. Proc. Natl. Acad. Sci. USA. 96:1999b;6937-6941.
89. Thut C. J., Goodrich J. A., Tjian R. Repression of p53-mediated transcription by MDM2: a dual mechanism. Genes Dev. 11:1997;1974-1986.
90. Kip1 is instigated by Jab1. Nature. 398:1999;160-165.
91. Toyoshima F., Moriguchi T., Wada A., Fukuda M., Nishida E. Nuclear export of cyclin B1 and its possible role in DNA damage-induced G2 checkpoint. EMBO J. 17:1998;2728-2735.
92. Tunac J. B., Graham B. D., Dobson W. E., Lenzini M. D. Novel antitumour antibiotics, CI-940 (PD 114,720) and PD 114,721. Taxonomy, fermentation and biological activity. J. Antibiotics. 38:1985;460-465.
93. Wada A., Fukuda M., Mishima M., Nishida E. Nuclear export of actin: A novel mechanism regulating the subcellular localization of a major cytoskeletal protein. EMBO J. 17:1998;1635-1641.
94. Wagner A. J., Kokontis J. M., Hay N. Myc-mediated apoptosis requires wild-type p53 in a manner independent of cell cycle arrest and the ability of p53 to induce p21waf1/cip1. Genes Dev. 8:1994;2817-2830.
95. Walker K. K., Levine A. J. Identification of a novel p53 functional domain that is necessary for efficient growth suppression. Proc. Natl. Acad. Sci. USA. 93:1996;15335-15340.
96. Weber J. D., Taylor L. J., Roussel M. F., Sherr C. J., Bar-Sagi D. Nucleolar Arf sequesters Mdm2 and activates p53. Nature Cell Biol. 1:1999;20-26.
97. Wilkinson C. R. M., Wallace M., Morphew M., Perry P., Allshire R., Javerzat J-P., McIntosh J. R., Gordon C. Localization of the 26S proteasome during mitosis and meiosis in fission yeast. EMBO J. 17:1998;6465-6476.
98. Wolff B., Sanglier J. J., Wang Y. Leptomycin B is an inhibitor of nuclear export: Inhibition of nucleo-cytoplasmic translocation of the human immunodeficiency virus type 1 (HIV-1) Rev protein and Rev-dependent mRNA. Chem. Biol. 4:1997;139-147.
99. Wu X., Bayle J. H., Olson D., Levine A. J. The p53-mdm-2 autoregulatory feedback loop. Genes Dev. 7:1993;1126-1132.
100. Xiong Y., Hannon G. J., Zhang H., Casso D., Kobagashi R., Beach D. p21 is a universal inhibitor of cyclin kinases. Nature. 366:1993;701-706.
101. Zhang Y., Xiong Y., Yarbrough G. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus impairs both the Rb and p53 tumour suppressor pathways. Cell. 92:1998;725-734.
102. Zhang Y., Xiong Y. Mutations in human ARF exon 2 disrupt its nucleolar localisation and impair its ability to block nuclear export of MDM2 and p53. Cell. 3:1999;579-591.
103. Zhu J., Woods D., McMahon M., Bishop J. M. Senescence of human fibroblasts induced by oncogenic Raf. Genes Dev. 12:1998;2997-3007.
104. Smart P., Lane E. B., Lane D. P., Midgley C., Vojtesek B., Laín S. Effects on normal fibroblasts and neuroblastoma cells of the activation of the p53 response by the nuclear export inhibitor leptomycin B. Oncogene. 1999.